People · Operator
Named in public records as an officer, director or promoter · active 2026–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Consano Bio, Inc. | — | Biotechnology | Series B | $59.6M | $120.9M | 2026 |
Christopher Vander Centeno at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Vander Centeno on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Hall | 1 | 4 |
| DANIEL HADERS | 1 | 2 |
| John Vander Conway | 1 | 1 |
| Joe Vander Schiesl | 1 | 1 |
| Jennifer Schmitke | 1 | 1 |
| Doug Vander Weide | 1 | 1 |
| Jerome Vander Adams | 1 | 1 |
| Chris Vander Centeno | 1 | 1 |
| WAYNE SCHELLHAMMER | 1 | 1 |
| Michael Vander Pede | 1 | 1 |
| CLAYTON HARTMAN | 1 | 1 |
| Bill Vander Abbington | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.